Sun Pharma and SPARC enter into licence agreement for commercialisation of phenobarbital for injection in US Read more
SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma Read more
SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target Read more
SPARC declares positive results from Phase 3 clinical trial of PDP-716 to treat open-angle glaucoma or ocular hypertension Read more
SPARC announces Phase 3 trial results of SDN-037 to treat inflammation and pain of ocular surgery Read more